CRWENews.com “Stock Watch Highlights: PWRM.OB

May 18, 2009 - PRLog -- Power3 Medical Products, Inc. (OTC Bulletin Board: PWRM - News), announced May 18, 2009 that results for early stage diagnosis from clinical validation trials of the NuroPro® PD test for Parkinson's disease were better than expected. The NuroPro PD test was developed to help clinicians distinguish patients with Parkinson's disease from "normal" individuals and patients with other neurological disorders. The test, developed by Power3, is a panel of blood serum protein biomarkers evaluated by biostatistical analysis to predict the probability a patient has Parkinson’s disease. The test is intended to solve the critical challenge facing physicians, clinicians, and patients for quick, early stage, and accurate diagnosis of this debilitating disease.  

“In the US, there are an estimated 1.5 million individuals with Parkinson’s disease.  Presently, annual treatment per patient is $25 thousand for Parkinson’s. Unfortunately, this disease is often misdiagnosed, and may take up to 10 years before the correct diagnosis is rendered. By the time patients are given a probable diagnosis, they have already suffered substantial and irreparable brain damage, rendering treatment less effective, even with existing drugs,” said Power 3's President and Chief Scientific Officer, Dr. Ira L. Goldknopf.

The latest results, from the completion of the first phase of clinical validation trials of the NuroPro® PD test, were found in blood serum samples from 52 Parkinson’s disease patients and 28 age matched normal controls from the University of Thessaly, Greece, as well as 6 Parkinson's disease patients and 50 age matched normal controls from Banner Sun Health Research Institute, Sun City, Arizona.

They not only show a sensitivity of 93.3% for detection of mild, moderate and severe Parkinson’s disease overall, as measured by two separate clinical scoring methods, but also that the sensitivity for early stage Parkinson’s disease patients was 100%.  The specificity of the test for correct diagnosis of normal individuals was 96.2%. “The fact that these results were obtained using fresh blood serum from patients, in the same way that the test will be performed in a clinical diagnostic setting, provides further support for the clinical usefulness of these findings,” commented Dr. Goldknopf.

Power3 is conducting the independent validation of both their Alzheimer's (NuroPro AD) and Parkinson's (NuroPro PD) tests with key clinical centers. The second phase of these prospective trials are being conducted with Katerina Markopoulou, M.D., Assistant Professor of Neurology at the University of Thessaly, Greece, principal investigator for Parkinson’s, and Marwan Sabbagh, M.D., Medical Director of the Banner Sun Health Research Institute in Sun City, AZ, principal investigator of the Alzheimer's study, and are slated for completion to launch of the Clia testing service in late 2009.

"The progress of the clinical validation achieved to date affirms our belief that NuroPro PD will help physicians make earlier diagnoses and recommend appropriate follow-up and treatment options for their patients," commented Helen R. Park, CEO of Power3.
We encourage investors to join and receive PinkSheetsIndex.com FREE e-mail news and stock watch alerts by visiting: www.pinksheetsindex.com.


About Power3 Medical Products, Inc
Power3 Medical Products (OTC BB: PWRM, www.power3medical.com) is a leader in bio-medical research and the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets, and its diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to complete phase II clinical validation trials of its blood serum diagnostics for Alzheimer's and Parkinson's disease (NuroPro AD and PD), in the fourth quarter of 2009, followed by completion of filing with the FDA. Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), and continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS, Alzheimer's, and Parkinson's diseases, breast cancer, and drug resistance.

Never invest in any stock featured on our sites, emails or alerts unless you can afford to lose your entire investment.
*********************************************************
The disclaimer is to be read and fully understood before using our sites, stock alerts or joining our email list.
CRWENews.com, PinkSheetsIndex.com and Crown Equity Holdings, Inc. associates, consultants, employees are not registered as Investment Advisor or Broker Dealer in any jurisdiction whatsoever. Full disclaimer can be read at http://www.crwenews.com.
Release of Liability: Through use of our website, Email Alerts, and stock alerts viewing or using, you agree to hold Crown Equity Holdings, Inc., its operators, shareholders, consultants, associates and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. CRWENews, PinkSheetsIndex.com and Crown Equity Holdings, Inc. affiliates and associates may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Crown Equity Holdings, Inc. encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and CRWENews.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies.

Forward-Looking Statement: This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements and/or Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

# # #

CRWENews.com is an independent electronic informative online financial news publication company dedicated in providing company associates, business and financial professionals with economic and investment information, as well as stock highlights.